B-cell lymphomas constitute the most frequent malignant neoplasm of the ocular adnexal, often presenting with localized disease. Five patients with primary localized CD20 positive B cell non Hodgkin ocular adnexal lymphomas received intralesional rituximab at the dose of 5mg once a week for one month, followed by 10mg weekly in case of incomplete response. Four of five patients obtained regression of symptoms and 2 of them showed complete response. No patients experienced side effects besides pain on the site of the injection. Local treatment with Rituximab for OAL is a safe and useful first-line therapeutic option.
Laurenti, L., De Padua, L., Battendieri, R., Tarnani, M., Sica, S., Blasi, M. A., Savino, G., Leone, G., Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation, <<LEUKEMIA RESEARCH>>, 2011; 35 (5): 682-684. [doi:10.1016/j.leukres.2011.01.030] [http://hdl.handle.net/10807/31826]
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation
Laurenti, Luca;De Padua, Laura;Battendieri, Remo;Tarnani, Michela;Sica, Simona;Blasi, Maria Antonietta;Savino, Giancarlo;Leone, Giuseppe
2011
Abstract
B-cell lymphomas constitute the most frequent malignant neoplasm of the ocular adnexal, often presenting with localized disease. Five patients with primary localized CD20 positive B cell non Hodgkin ocular adnexal lymphomas received intralesional rituximab at the dose of 5mg once a week for one month, followed by 10mg weekly in case of incomplete response. Four of five patients obtained regression of symptoms and 2 of them showed complete response. No patients experienced side effects besides pain on the site of the injection. Local treatment with Rituximab for OAL is a safe and useful first-line therapeutic option.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
